Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Policy

Democrats Urge NIH To Fight Price-Gouging

by Glenn Hess,
February 1, 2016 | A version of this story appeared in Volume 94, Issue 5

Fifty-one Democrats in the House of Representatives are calling on the National Institutes of Health to use its authority to help curtail rising prescription drug prices. Led by Rep. Lloyd Doggett (D-Texas), the lawmakers want NIH to develop guidelines for overriding patent protections on pricey drugs developed with federal funding. The 1980 Bayh-Dole Act gives NIH so-called march-in rights, which empower the agency to open up branded drugs to generics competition. The law allows an agency that funds private research to require a drugmaker to license its patent to another manufacturer to “alleviate health and safety needs which are not being reasonably satisfied” or when the benefits of the drug are not “available to the public on reasonable terms.” In a letter to NIH Director Francis S. Collins, the lawmakers argue that clear guidelines on the issue could “discourage drug price-gouging.” NIH has previously taken the stance that controlling drug prices is a congressional responsibility. It has rejected five previous requests to use march-in rights.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.